ASCO 2012: Radium-223 and Prostate Cancer Survival
August 20, 2012|Oncology Practice
Author and Disclosure Information
Dr. Chris Parker of Royal Marsden Hospital in London discusses the ALSYMPCA trial of radium-223 (Alpharadin), the first agent to improve prostate cancer survival by targeting bone metastases.